On Friday, the MHRA announced it had identified 30 cases of rare blood clots among the 18.1 million people vaccinated with this formula by the end of March.
The health regulator pointed out that the risks associated with these clots are “very small” and that the population must continue to accept the vaccine when offered by health services.
Of the 30 incidents, 22 correspond to cerebral venous thrombosis (CVT) and the remaining eight are related to low platelets.According to the MHRA, seven of these vaccinated people have died and investigations are underway to ascertain the link between the deaths and the AstraZeneca vaccine.
MHRA director June Raine says in the statement that no similar case has been reported for the Pfizer / BioNTech vaccine.
“The advantages of the AstraZeneca vaccine to prevent infection with covid-19 and its complications continue to be far greater than the risks and the public should continue to receive the vaccine,” said Raine.
In addition to the Astrazeneca vaccine, the United Kingdom is also using the Pfizer formula. To date, more than 30 million people have received at least the first of two doses of one of these vaccines.
The appearance of cases of blood clots and deaths of people inoculated with this drug has led most European countries, including Portugal, to suspend the administration of this vaccine for a few days, a situation that was overcome after the EMA’s guarantee that it is “safe and effective”. .
Still, some countries, such as Norway, maintain the suspension and others, such as Germany, limit vaccination with this vaccine to those over 60 years of age.
Get the latest news delivered to your inbox
Follow us on social media networks